Core Viewpoint - The company is focusing on the development of its ATTC (Antibody-Drug Conjugate) platform and plans to seek partnerships with multinational pharmaceutical companies for the development of ATTC candidate drugs in 2026 [9]. Financial Performance - For the fiscal year ending December 31, 2025, the company's revenue is projected to be $548.5 million, an increase from $630.2 million in 2024 [2]. - The net income attributable to the company for 2025 is expected to be $456.9 million, significantly up from $37.7 million in 2024, primarily due to a $415.8 million after-tax gain from the sale of a stake in Shanghai Hengrui Medicine [2]. - As of the end of 2025, the company’s cash reserves are expected to total $1.3673 billion, up from $836.1 million the previous year, providing ample funding for the global development of its ATTC platform [2]. Market Performance - As of March 6, the stock price of the company increased by 8.4%, with an intraday high of 9.6% [3]. - The total market sales for 2025, including products like FRUZAQLA®, Aiyoute®, Suotai Da®, and Worisha®, are projected to grow by 5% to reach $524.7 million [5]. Product Development - The overseas sales of FRUZAQLA® (Fruquintinib) increased by 26% to $36.62 million, covering 38 countries, with nearly 20 countries included in health insurance [5]. - The company has received approval for a third indication for lung cancer for Worisha® (Savolitinib), triggering a $11 million milestone payment from AstraZeneca [5]. - The clinical pipeline is advancing, with the ESLIM-02 Phase III study achieving its primary endpoint in autoimmune hemolytic anemia, and plans to submit a new drug application in the first half of 2026 [6]. ATTC Platform Development - The ATTC platform has entered clinical trial stages, with the first candidate drug HMPL-A251 starting global Phase I/IIa trials in December [8]. - The company plans to accelerate global investment in the ATTC projects, with a focus on innovative drug development in oncology [10].

Global Commercial Portfolio Next-generation Innovative Platform March 2026 HKEX:13 | Nasdaq/AIM:HCM 1 Safe Harbor Statement & Disclaimer The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results. The performance and results of operations of the Group contained within this presentation are historical in nature, and past performance is no guarantee of future results of the Group. This pres ...

Financial Performance & Divestment - HUTCHMED reported profits of $455 million in H1 2025, driven by a $477.5 million gain from the partial divestment of SHPL[15] - The company divested a 45% equity interest in SHPL, retaining 5%, resulting in gross proceeds of $609 million[13] - HUTCHMED's cash, cash equivalents, and short-term investments totaled $1,364.5 million as of June 30, 2025[12] - Oncology revenue was $143.5 million in H1 2025, a decrease from $168.7 million in H1 2024[15] - The company revised its 2025 Oncology Revenue Guidance to $270 million - $350 million, down from the previous guidance of $350 million - $450 million[20] Commercial Product Performance - FRUZAQLA® in-market sales grew by 25% to $162.8 million in H1 2025[10, 22] - ELUNATE® in-market sales decreased by 29% to $43.0 million in H1 2025[22] - ORPATHYS® in-market sales decreased by 41% to $15.2 million in H1 2025[22] - SULANDA® in-market sales decreased by 50% to $12.7 million in H1 2025[22] Pipeline & Development - The company is developing an Antibody-Targeted Therapy Conjugate (ATTC) platform with multiple drug candidates, with the first candidate US + China clinical trial initiation expected in H2 2025[10] - Savolitinib received China NMPA approval in June 2025 for 2L NSCLC MET amplification[10, 36, 46]

GLOBAL COMMERCIAL PORTFOLIO NEXT-GENERATION INNOVATIVE PLATFORM 0000po HUTCHMED August 2025 Nasdaq/AIM:HCM | HKEX:13 Safe harbor statement & disclaimer The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results. apat performance is no guarantee of future results of the Group. This presentation cortains for na d-looking statements filings with the US Securities and Endorge Commis within th ...

Financial Performance & Cash Position - HUTCHMED achieved profitability ahead of schedule, driven by strong performance of FRUZAQLA®[100] - The company's cash, cash equivalents, and short-term investments amounted to $836 million as of December 31, 2024[14] - Oncology revenue reached $3634 million in 2024, including $271 million from oncology products revenue and $71 million from royalties[18] - The company projects oncology revenue guidance of $350-$450 million for 2025[18] Commercial Success & Growth - Global in-market sales of oncology products reached $501 million in 2024, a 134% increase compared to $2136 million in 2023[20] - FRUZAQLA® in-market sales were $2906 million in 2024, a significant increase from $151 million in 2023, representing a growth of +1,825%[20] - ELUNATE® in-market sales reached $115 million in 2024, a 7% increase from $1075 million in 2023[20] - SULANDA® in-market sales were $49 million in 2024, a 12% increase from $439 million in 2023[20] Pipeline Development & Regulatory Milestones - The company has 13+ potential NDAs & sNDAs in the next 3 years[45] - Fruquintinib received conditional approval in China for endometrial cancer in December 2024[49] - A Phase III study of Fruquintinib (FRUSICA-2) in 2L RCC showed positive topline results, with China NDA filing expected[47]